Daridorexant as a novel pharmacotherapeutic approach in insomnia: a systematic review and meta-analysis

References

• Colrain IM Sleep and the brain. Neuropsychol rev. 2011 Mar;21(1):1–4. doi: 10.1007/s11065-011-9156-z
   PubMed Web of Science ®Google Scholar
• Khaled SM, Petcu C, Al-Thani MA, et al. Prevalence and associated factors of DSM-5 insomnia disorder in the general population of qatar. BMC Psychiatry. 2021 Feb 8;21(1):84. doi: 10.1186/s12888-020-03035-8
   PubMed Web of Science ®Google Scholar
• Morin CM, Drake CL, Harvey AG, et al. Insomnia disorder. Nat Rev Dis Primers. 2015 Sep 3;1(1):15026. doi: 10.1038/nrdp.2015.26
   PubMedGoogle Scholar
• Bhaskar S, Hemavathy D, Prasad S Prevalence of chronic insomnia in adult patients and its correlation with medical comorbidities. J Family Med Prim Care. 2016 Oct;5(4):780–784. doi: 10.4103/2249-4863.201153
   PubMedGoogle Scholar
• Dopheide JA. Insomnia overview: epidemiology, pathophysiology, diagnosis and monitoring, and nonpharmacologic therapy. Am J Manag Care. 2020 Mar;26(4 Suppl):S76–s84.
   PubMed Web of Science ®Google Scholar
• Worley SL The extraordinary importance of sleep: the detrimental effects of inadequate sleep on health and public safety drive an explosion of sleep research. Phar Ther. 2018 Dec;43(12):758–763. doi: 10.5664/jcsm.7176
   Google Scholar
• Williams J, Roth A, Vatthauer K, et al. Cognitive behavioral treatment of insomnia. Chest. 2013 Feb 1;143(2):554–565. doi: 10.1378/chest.12-0731
   PubMed Web of Science ®Google Scholar
• Liu MT. Current and emerging therapies for insomnia. Am J Manag Care. 2020 Mar;26(4 Suppl):S85–s90.
   PubMed Web of Science ®Google Scholar
• Abad VC, Guilleminault C Insomnia in elderly patients: recommendations for pharmacological management. Drugs Aging. 2018 Sep;35(9):791–817. doi: 10.1007/s40266-018-0569-8
   PubMed Web of Science ®Google Scholar
• Lie JD, Tu KN, Shen DD, et al. Pharmacological treatment of Insomnia. Phar Ther. 2015 Nov;40(11):759–771. doi: 10.1176/appi.books.9780890425596.dsm12
   Google Scholar
• Zammit G, Dauvilliers Y, Pain S, et al. Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder. Neurology. 2020 May 26;94(21):e2222–e32. doi: 10.1212/WNL.0000000000009475
   PubMed Web of Science ®Google Scholar
• Jacobson LH, Hoyer D, de Lecea L Hypocretins (orexins): the ultimate translational neuropeptides. J Intern Med. 2022 May;291(5):533–556. doi: 10.1111/joim.13406
   PubMed Web of Science ®Google Scholar
• Roch C, Bergamini G, Steiner MA, et al. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia. Psychopharmacology. 2021 Oct;238(10):2693–2708. doi: 10.1007/s00213-021-05954-0
   PubMed Web of Science ®Google Scholar
• Markham A Daridorexant: first approval. Drugs. 2022 Apr;82(5):601–607. doi: 10.1007/s40265-022-01699-y
   PubMed Web of Science ®Google Scholar
• Idorsia Pharmaceuticals Ltd: Europe’s first dual orexin receptor antagonist – Daridorexant (QUVIVIQ) – granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder [Internet]. 2022 May 3 [cited May 16, 2023]. Available from: https://finance.yahoo.com/news/europe-first-dual-orexin-receptor-050000256.html
   Google Scholar
• US FDA. Daridorexant (“QUVIVIQ”) tablets, for oral use controlled substance schedule pending]; Initial U.S. Approval: [pending controlled substance scheduling] 2022. [[updated 2022; cited 2022 Jul 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214985s000lbl.pdf
   Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Clin Res Ed). 2011 Oct 18;343:d5928. doi: 10.1136/bmj.d5928
   PubMedGoogle Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clin Res Ed). 2019 Aug 28;366:l4898. doi: 10.1136/bmj.l4898
   PubMedGoogle Scholar
• McGuinness LA, Higgins JPT. Risk-of-bias visualization (robvis): An R package and shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2020 2020 Apr 26;12:55–61. doi: 10.1002/jrsm.1411
   PubMed Web of Science ®Google Scholar
• McMaster University and Evidence Prime. Gradepro GDT: GRADEpro guideline development tool [software]. [ cited 2022 Sep 22]. Available from: gradepro.org
   Google Scholar
• Schünemann HB, Guyatt G, Oxman A GRADE handbook for grading quality of evidence and strength of recommendations. 2013 [cited 2022 Sep 22]. Available from: guidelinedevelopment.org/handbook.
   Google Scholar
• The Cochrane Collaboration. Cochrane training Cochrane review manager (RevMan) 2022. [updated 2022; cited 2022 Jul 28]. Available from: https://training.cochrane.org/online-learning/core-software/revman
   Google Scholar
• The Cochrane Collaboration. Heterogeneity: Cochrane Training Cochrane Handbook for Systematic Reviews of Interventions. 2022 [updated 2022; cited 2022 Jul 29]. Available from: https://training.cochrane.org/handbook/current/chapter-10#section-10-10
   Google Scholar
• The Cochrane Collaboration. Fixed or random effects? Cochrane training Cochrane handbook for systematic reviews of interventions. 2022 [updated 2022; cited 2022 Aug 1]. Available from: https://training.cochrane.org/handbook/current/chapter-10#section-10-10-4-1
   Google Scholar
• Efficacy and safety of ACT-541468 in adult subjects with insomnia disorder (NCT02839200) [Internet]. 2020 [cited Aug 2, 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT02839200
   Google Scholar
• Study to assess the efficacy and safety of ACT-541468 (daridorexant) in adult and elderly subjects with insomnia disorder (NCT03545191) [Internet]. ClinicalTrials.gov. 2022 [cited Aug 2, 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT03545191
   Google Scholar
• Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep(NCT03679884) [Internet]. 2022 [cited Aug 2, 2022]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT03679884
   Google Scholar
• Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep(NCT03575104) [Internet]. 2022 [cited Aug 2, 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT03575104
   Google Scholar
• Dauvilliers Y, Zammit G, Fietze I, et al. Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder. Ann Neurol. 2020 Mar;87(3):347–356. doi: 10.1002/ana.25680. Erratum in: Ann Neurol. 2020 Sep;88(3):647-651.
   PubMed Web of Science ®Google Scholar
• Dos Santos JBR, da Silva MRR, da Silva MRR Daridorexant for the treatment of insomnia disorder: findings and implications. Eur J Clin Pharmacol. 2022 Sep 13;78(11):1749–1761. doi: 10.1007/s00228-022-03381-4
   PubMed Web of Science ®Google Scholar
• Mignot E, Mayleben D, Fietze I, et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol. 2022 Feb;21(2):125–139. doi: 10.1016/S1474-4422(21)00436-1
   PubMed Web of Science ®Google Scholar
• Schilling U, Henrich A, Muehlan C, et al. Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis. Clin Drug Investig. 2021 Aug;41(8):711–721. doi: 10.1007/s40261-021-01062-1
   PubMed Web of Science ®Google Scholar
• Fietze I, Bassetti CLA, Mayleben DW, et al. Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial. Drugs Aging. 2022 Oct 01;39(10):795–810.
   PubMed Web of Science ®Google Scholar
• Muehlan C, Brooks S, Vaillant C, et al. Driving Performance after Bedtime Administration of Daridorexant, Assessed in a Sensitive Simulator. Clin Pharmacol Ther. 2022 Jun;111(6):1334–1342. doi: 10.1002/cpt.2592
   PubMed Web of Science ®Google Scholar
• Ufer M, Kelsh D, Schoedel KA, et al. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem. Sleep. 2022 Mar 14;45(3). doi: 10.1093/sleep/zsab224
   PubMed Web of Science ®Google Scholar
• Glass J, Lanctôt KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ (Clin Res Ed). 2005 Nov 19;331(7526):1169. doi: 10.1136/bmj.38623.768588.47
   PubMedGoogle Scholar
• Muehlan C, Heuberger J, Juif P-E, et al. Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human Study. Clin Pharmacol Ther. 2018;104(5):1022–1029. doi: 10.1002/cpt.1046
   PubMed Web of Science ®Google Scholar
• Winkler A, Auer C, Doering BK, et al. Drug treatment of primary insomnia: a meta-analysis of polysomnographic randomized controlled trials. CNS Drugs. 2014 Sep;28(9):799–816. doi: 10.1007/s40263-014-0198-7
   PubMed Web of Science ®Google Scholar
• Ehlers CL, Benedict J, Wills D, et al. PSPH-D-18-00526: Effect of a dual orexin receptor antagonist (DORA-12) on sleep and event-related oscillations in rats exposed to ethanol vapor during adolescence. Psychopharmacol (Berl). 2020 Oct;237(10):2917–2927. doi: 10.1007/s00213-019-05371-4
   PubMed Web of Science ®Google Scholar
• Lee MG, Hassani OK, Jones BE Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci. 2005 Jul 13;25(28):6716–6720. doi: 10.1523/JNEUROSCI.1887-05.2005
   PubMed Web of Science ®Google Scholar
• Parks GS, Warrier DR, Dittrich L, et al. The Dual Hypocretin Receptor Antagonist Almorexant is Permissive for Activation of Wake-Promoting Systems. Neuropsychopharmacology. 2016 Mar;41(4):1144–1155. doi: 10.1038/npp.2015.256
   PubMed Web of Science ®Google Scholar
• Scammell TE, Arrigoni E, Lipton JO Neural Circuitry of Wakefulness and Sleep. Neuron. 2017 Feb 22;93(4):747–765. doi: 10.1016/j.neuron.2017.01.014
   PubMed Web of Science ®Google Scholar
• Robinson CL, Supra R, Downs E, et al. Daridorexant for the Treatment of Insomnia. Health Psychol Res. 2022;10(3):37400. doi: 10.52965/001c.37400
   PubMed Web of Science ®Google Scholar
• Albadrani MS, Albadrani MS, Fadlalmola HA, et al. Safety and efficacy of daridorexant in the treatment of insomnia: a systematic review and meta-analysis of randomized controlled trials. Int Clin Psychopharmacol. 2023 Jan 1;38(1):57–65. doi: 10.1097/YIC.0000000000000425
   PubMed Web of Science ®Google Scholar
• Mangoni AA, Jackson SH Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004 Jan;57(1):6–14. doi: 10.1046/j.1365-2125.2003.02007.x
   PubMed Web of Science ®Google Scholar
• Boof ML, Ufer M, Fietze I, et al. Assessment of the effect of the dual orexin receptor antagonist daridorexant on various indices of disease severity in patients with mild to moderate obstructive sleep apnea. Sleep Med. 2022 Apr;92:4–11.
   PubMed Web of Science ®Google Scholar
• Ziemichód W, Grabowska K, Kurowska A, et al. A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia. Molecules. 2022 Sep 16;27(18):6041. doi: 10.3390/molecules27186041
   PubMed Web of Science ®Google Scholar